[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587438":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":57,"collaborators":11,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":11,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":11,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Akeso","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ivonescimab and docetaxel","EXPERIMENTAL",null,[13],"Drug: Ivonescimab, docetaxel",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo and docetaxel","ACTIVE_COMPARATOR",[18],"Drug: Placebo, docetaxel",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Ivonescimab, docetaxel","Patients will receive ivonescimab and docetaxel as an IV injection",[9],[26],"AK112, docetaxel",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"Placebo, docetaxel","Patients will receive placebo and docetaxel as an IV injection",[15],[32],{"name":33,"affiliation":34,"role":35},"Caicun Zhou","Shanghai East Hospital","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Wenting Li","CONTACT","18116403289","wenting01.li@akesobio.com",[43],{"facility":34,"status":44,"city":45,"state":46,"zip":11,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Shanghai","Shanghai Municipality","China","CN",{"type":50,"coordinates":51},"Point",[52,53],121.45806,31.22222,{"lat":53,"lon":52},[56],{"name":33,"role":39,"phone":11,"phoneExt":11,"email":11},{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100587438","phase-3-ivonescimab-in-combination-with-docetaxel-in-advanced-non-small-cell-lung-cancer-100587438",false,"NCT06928389","Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","A Randomized, Double-blind, Multicenter Phase 3 Clinical Trial of Ivonescimab Versus Placebo, Combined With Docetaxel in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) That Has Progressed on or After PD-(L)1 Inhibitor-based Therapy","NSCLC","Inclusion Criteria:\n\n* Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).\n* Age ≥ 18 years old and ≤ 75 years old at the time of randomization.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Expected life expectancy of at least 3 months.\n* Histologically or cytologically confirmed diagnosis of NSCLC.\n* Locally advanced or metastatic NSCLC (American Joint Committee on Cancer \\[AJCC\\] 8th edition).\n* Previously received systemic platinum-based chemotherapy and PD-1\u002FL1 inhibitors.\n* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Histologic or cytopathologic evidence of the presence of small cell lung carcinoma.\n* Other malignancies within 3 years prior to randomization.\n* Known actionable genomic alterations.\n* Prior administration of any immunotherapy targeting immune mechanisms other than PD-1\u002FPD-L1 inhibitors.\n* Previous treatment with docetaxel.\n* History of severe bleeding tendency or coagulation dysfunction.\n* Active autoimmune disease requiring systemic therapy within 2 years prior to randomization.\n* History of myocarditis, cardiomyopathy, and malignant arrhythmia.","ALL","18 Years","75 Years",{"count":71,"type":72},536,"ESTIMATED","INTERVENTIONAL",[75],"PHASE3","This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based therapy. The purpose of this study is to evaluate the efficacy and safety of ivonescimab versus placebo, combined with docetaxel in patients with advanced NSCLC.",[78],"Non-Small Cell Lung Cancer","2026-04-07",{"date":81,"type":82},"2026-04-09","ACTUAL",{"date":84,"type":82},"2025-07-08",{"date":86,"type":72},"2030-06",{"name":5,"class":6},1]